Navigation Links
INFORM-1 Clinical Trial Amended to Further Explore Promising Direct Antiviral Regimen in HCV Patients
Date:4/21/2009

- Non-responder and Null Responder HCV patients -

- Twice-Daily Dosing and Higher Doses of ITMN-191 (R7227) -

BRISBANE, Calif., April 21 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that the innovative clinical study of protease inhibitor ITMN-191 (R7227) in combination with nucleoside polymerase inhibitor R7128 (Roche/Pharmasset), referred to as the INFORM-1 study, has been successfully amended to include additional cohorts to explore the combination in treatment-experienced and null responder HCV patients. In addition, the amended protocol now includes the administration of twice-daily and higher-dose regimens of ITMN-191 in combination with R7128 in treatment-naive patients. A description of the expanded study design can be viewed at .

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "The first four cohorts of the INFORM-1 study successfully demonstrated that the novel combination of relatively low doses of two direct antiviral agents can be administered safely and, in the absence of interferon, result in robust antiviral activity in treatment-naive HCV patients. INFORM-1 has now been expanded to explore this novel regimen in treatment-experienced patients; both non-responder patients and so-called null responders, which together represent an important unmet medical need as their treatment options are currently very poor. The inclusion of twice-daily dosing of ITMN-191 at doses of up to 900mg, doses that were safely and effectively explored when combined with the current standard of care, is another important expansion of INFORM-1. We look forward to the results of these important new cohorts."

INFORM-1 Expanded Study Design

The expanded INFORM-1 design now includes three additional dosage cohorts
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. INFORM-1 Interim Results Accepted for Late-Breaker Presentation at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
11. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013  Moderna Therapeutics, the ... treatment modality to enable the in vivo ... John Reynders will join Moderna in early ... Reynders is a proven leader in the design ... drug development, from discovery to translation, clinical operations and ...
(Date:5/21/2013)... 2013  The Lindsley F. Kimball Research Institute of the ... Grand Challenges Explorations winner, an initiative funded by ... Sara Lustigman , Head of the Laboratory of ... research project, titled Innovative 3-D in vitro ... to screen drugs to help eliminate onchocerciasis (river blindness) in ...
(Date:5/21/2013)... The results of a new study led by ... computational evidence that nucleation of ice in small ... understanding water,s behavior at the nanoscale. The formation ... basic scientific research question whose answer also has ... , The crystallization of ice from supercooled ...
(Date:5/21/2013)... Savoury Systems International (SSI), a leader in the ... USA Sales Broker. Braddy’s new role will allow SSI ... , In 2004 Braddy founded Southeastern Food ... processors and industrial manufacturers. Braddy has worked for ... has over 25 years of sales management experience. ...
Breaking Biology Technology:Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2
... biopharmaceutical industry information on ... ... BioSpace, the world,s leading,online community for the bioscience industry, launched ... medical,devices industries in Europe. EuroBio(TM) features dynamic informational,Hotbed Web pages ...
... 18 ARUP Laboratories, a national,clinical and anatomic ... research and development, announced today that it has,entered ... LLC,(PSA), a nationwide network affiliation and a principal ... practices. The,agreement, effective June 17, 2008, offers special ...
... Treatment, Predicting Risk of Gastric Cancer Recurrence, ... Lung Cancer, In Addition, the Company has Identified Unique microRNA Biomarkers in ... for a Future ... Test for Colon Cancer, New Tests Expected ...
Cached Biology Technology:BioSpace Launches EuroBio(TM) Online Community 2ARUP Laboratories Partners With Pathology Service Associates 2ARUP Laboratories Partners With Pathology Service Associates 3Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 2Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 3Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 4Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development 5
(Date:5/21/2013)... a whale entangled in fishing gear, scientists showed for ... diving and swimming behavior. The monitoring revealed how fishing ... their energy as they drag gear for months or ... The scientists in this entanglement response suction-cupped a cellphone-size ... Atlantic right whale called Eg 3911. The Dtag, developed ...
(Date:5/21/2013)... Wash. A new analysis shows that the nation,s ... of enough algae to produce up to 25 billion ... States, one-twelfth of the country,s yearly needs. , The ... resources that would be needed to grow significant amounts ... results were published in the May 7 issue of ...
(Date:5/21/2013)... found that a class of pharmaceuticals can both prevent ... drugs, known as "TSPO ligands," are currently used for ... effects of TSPO ligand in young adult mice when ... mice when pathology was quite severe," said lead researcher ... "TSPO ligand reduced measures of pathology and improved behavior ...
Breaking Biology News(10 mins):Study reveals how fishing gear can cause slow death of whales 2Study reveals how fishing gear can cause slow death of whales 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2
... Arlington, VA November 2, 2010 CONRAD, leaders ... $5 million award from the US Agency for International Development ... vaginal rings that are contraceptive and also prevent HIV and ... CAPRISA 004 trial of tenofovir gel, conducted by the Centre ...
... one knows better "The Promise of Human Genetics" than the ... Washington D.C. on Wednesday: this year,s Gruber Genetics Prize recipient ... to "grow" genes in yeast, thus allowing scientists to create ... how cells inherit information. It is Fink whose "transforming" technique ...
... conducted in the context of the Swiss National Research Programme ... for the first time that internal exposure of humans to ... of the Summer and Fall 2004, 2005 and 2006 (3 ... birth at the University Women,s Hospital in Basel. The participants ...
Cached Biology News:USAID awards $5 million to CONRAD 2Fink receives Gruber Genetics Prize, lectures at American Society of Human Genetics annual meeting 2Exposure of humans to cosmetic UV filters is widespread 2Exposure of humans to cosmetic UV filters is widespread 3
... ISO 9001:2000 Certified USDA Research Registered OLAW ... Training AALAS Certified Technicians ... GLP Documentation Upon Request Focus ... for all your custom immunology service needs. ...
Request Info...
... ,ICC and IHC Protocol Development ,Antibody ... Screenings in Animal or Human Cells ... Cells and Tissues ,Peroxidase, Alkaline Phosphatase, ... or Electron Microscopy ,Protein Localization in ...
Request Info...
Biology Products: